Prime Medicine, Inc.

NASDAQ:PRME

Biotechnology

Healthcare
$3.82 -1.11%

-$0.04 today

Market cap
$694.94M
Beta
2.31
P/E (TTM)
-2.8
EPS (TTM)
-$1.12
52W Low $1.77High $6.94

Volume 4.62M

Average 2.47M

PRME Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Prime Medicine, Inc.NASDAQ: PRME

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $1.86M, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $47.71M.

Context

  • Cost of revenue amounted to 158.1% of revenue in FY2025, up 158.1 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $1.86M or moves back toward the trailing-twelve-month quarterly average of $11.93M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.86M— QoQ
Last fiscal yearDec 2025
$7.32M— YoY
LTMMar 2026
$47.71M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
7.32M USD
Year-over-year change
—

Cost of Revenue vs competitors

How PRME compares with its peers on the latest reported figures

  • PRME's LTM Mar 2026 cost of revenue of $47.71M is the 3rd highest of the 7 companies compared; the peer median is $19.19M.
  • Cost of revenue amounts to 1182.7% of revenue for PRME, versus a peer median of 94.2%.
PRME Competitors Peer median
Cost of Revenue for PRME and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$167.7M -26.7%+28.1%253.7%
CRSPCRISPR Therapeutics AGLTM Sep 2026$165.86M -3.5%+28.3%658.9%
PRMEPrime Medicine, Inc.LTM Mar 2026$47.71M ——1182.7%
EDITEditas Medicine, Inc.LTM Mar 2026$36.44M -53.4%—94.2%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$1.95M -96.9%+0.0%17.4%
BEAMBeam Therapeutics Inc.LTM Jun 2026$0 —-58.5%0.0%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$0 -100.0%+10.1%—
SCTXScribe Therapeutics Inc.—— ———
Peer median (excluding PRME) $19.19M-53.4%+10.1%94.2%

Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0002.98M4.63M
Cost of Revenue00007.32M
Gross Profit0002.98M(2.69M)
Gross Margin———100.0%-58.1%
Research & Development70.55M86.73M147.91M155.29M160.64M
Selling, General & Admin13.92M29.82M43.39M50.16M52.35M
Operating Expenses84.47M116.54M204.79M205.45M205.66M
Depreciation & Amortization568K2.22M4.65M6.13M5.38M
EBITDA(165.29M)(120.55M)(186.64M)(189.75M)(195.76M)
EBITDA Margin———-6361.2%-4226.2%
Operating Income(84.47M)(116.54M)(204.79M)(202.47M)(208.35M)
Operating Margin———-6787.4%-4498.1%
Interest Income0003.52M4.15M
Interest Expense00000
Other Income / Expenses(81.38M)(6.23M)6.38M6.59M7.21M
Income Before Tax(165.85M)(122.77M)(198.41M)(195.88M)(201.14M)
Pre-Tax Margin———-6566.6%-4342.4%
Income Tax Expense(486K)(948K)(279K)00
Net Income(165.37M)(121.82M)(198.13M)(195.88M)(201.14M)
Net Margin———-6566.6%-4342.4%
EPS (Basic)(1.92)(1.46)(2.18)(1.65)(1.35)
EPS (Diluted)(1.92)(1.46)(2.18)(1.65)(1.35)
Weighted Avg Shares95.73M97.21M90.97M118.6M148.76M
Weighted Avg Shares (Diluted)95.73M97.21M90.97M118.6M148.76M

Prime Medicine, Inc.

NASDAQ:PRME

Intrinsic Alpha fair value

Locked

Current Price

$3.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.